We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current 1OGN market cap is 3.7B. The company's latest EPS is USD 3.9722 and P/E is 3.85.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 9.53B | 8.1B | 6.3B | 6.17B | 6.26B |
| Operating Income | 3.55B | 2.71B | 1.81B | 1.57B | 1.26B |
| Net Income | 3.22B | 2.16B | 1.35B | 917M | 1.02B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 10.55B | 9.92B | 10.68B | 10.96B | 12.06B |
| Total Liabilities | 3.51B | 4.43B | 12.19B | 11.85B | 12.13B |
| Total Equity | 7.04B | 5.49B | -1.51B | -892M | -70M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 2.77B | 2.19B | 2.46B | 858M | 799M |
| Investing | -102M | -258M | -481M | -420M | -260M |
| Financing | -2.62B | -2.18B | -1.33B | -433M | -569M |
| Market Cap | 3.7B |
| Price to Earnings Ratio | 3.85 |
| Price to Sales Ratio | 0.63 |
| Price to Cash Ratio | 5.69 |
| Price to Book Ratio | -56.33 |
| Dividend Yield | 8.18% |
| Shares Outstanding | 257.54M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 21.97% |
| 52 Week High | 21.47 |
| 52 Week Low | 11.79 |
| Spread (Intraday) | 2.98 (17.6%) |
| Company Name | Organon & Co |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.organon.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
